Protein expression of epidermal growth factor receptor in laryngeal squamous cell carcinoma index tumors correlates with diagnosis of second primary tumors of the upper aero-digestive tract

Annals of Surgical Oncology

Volumn 16, Issue 10, 2009, Pages 2888-2894

  Farhadieh, Ross Darius ^a,b   Salardini, Arash ^c,d   Gordon Rees, Charles Geoffrey ^d   Russell, Pamela J ^a   Yang, Jia Lin ^d   Smee, Robert ^a,d  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c YALE UNIVERSITY   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN MDM2; EGFR PROTEIN, HUMAN; MDM2 PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNGEAL SQUAMOUS CELL CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; SECOND CANCER; CANCER STAGING; COHORT ANALYSIS; ENZYME IMMUNOASSAY; FOLLOW UP; LARYNX TUMOR; METABOLISM; PATHOLOGY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LARYNGEAL NEOPLASMS; MALE; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 73349098758     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-009-0649-4     Document Type: Article

References (34)

1. Licitra L, Locati LD. Head and neck cancer. Ann Oncol. 2004;15(4):267-73.
2. Pisani P, Bray F, Parkin DM. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer. 2002;97:72-81.
3. Ang KK, Berkey BA, Tu X. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-6.
4. Lin K, Patel SG, Chu PY, et al. Second primary malignancy of the aerodigestive tract in patients treated for cancer of the oral cavity and larynx. Head Neck. 2005;27:1042-8.
5. Vaamonde P, Martin C, del Rio M, LaBella T. second primary malignancies in patients with cancer of the head and neck. Oto-larngol Head Neck Surg. 2003;129:65-70.
6. Momand J, Zambetti GP, Olson DC, et al. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell. 1992;69:1237-45.
7. Michael D, Oren M. The p53 and MDM2 families in cancer. Curr Opin Genet Dev. 2002;12:53-9.
8. Zhang Z, Wang H, Li M, et al. MDM2 as a negative regulator of p21 WAF1/CIP1, independent of p53. J Biol Chem. 2004;279: 16000-6.
9. Pomerantz J, Schreiber-Agus N. The Ink4a tumour suppressor gene product, pARF19, interacts with MDM2 neutralises MDM2 inhibition of p53. Cell. 1998;92:713-23.
10. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncogene MDM2. Nature. 1995;375:694-8.
11. Grandis J, Melhem M, Gooding W. Levels of TGF-a and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824-32.
12. Grandis J, Tweardy D. Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579-84.
13. Grandis J, Tweardy D, Melhem M. Asynchronous modulation of transforming growth factor alpha and epidermal growth factor receptor protein expression in progression of premalignant lesions to head and neck cancer. Clin Cancer Res. 1998;4:13-20.
14. Grandis R, Melhem M, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor alpha and transforming growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 1996;78:1284-92.
15. Maurizi M, Almadori G, Ferrandina G. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 1996;74:1253-7.
16. Miyaguchi M, Olofosson J, Hellquist HB. Expression of epider-mal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol. 1991;16:466-9.
17. Wen QH, Miwa T, Yoshizaki T. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope. 1996;106:884-8.
18. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetux-imab for squamous cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-78.
19. De Vries N, Snow GB. Multiple primary tumours in patients with laryngeal cancer. J Layngol Otol. 1986;100:915-8.
20. Ch'ng S, Lowe I, Ng D, et al. Epidermal growth factor receptor: a novel biomarker for aggressive head and neck cutaneous squa-mous cell carcinoma. Hum Pathol. 2008;39:344-9.
21. Leemans CR, Tiwari R, Nauta JJ, et al. Regional lymph node involvement and its significance in the development of distant metastases in head and neck carcinoma. Cancer. 1993;71:452-6.
22. Farhadieh RD, Smee R, Rees CG, et al. Cyclin A1 expression in laryngeal cancers correlates with diagnosis of new HNSCCs primary. ANZ J Surg. 2009;79:48-54.
23. Jorissen RN, Walker F, Pouliot N, et al. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res. 2003;284:31-53.
24. Ang KK, Milas L. Epidermal growth factor receptor and response of head and neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58:959-65.
25. Zhang X, Chen Z, Choe MS, et al. Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res. 2005;11:6261-9.
26. Chen Z, Zhang X, Li M, et al. Simultaneously targeting epider-mal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004;10:5930-9.
27. Braakhuis BJM, Tabor MP, Leemans CR, et al. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head Neck. 2002;24:198-206.
28. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, et al. Multiple head and neck tumors frequently originate from a single prene-oplastic lesion. Am J Pathol. 2002;161:1051-60.
29. Braakhuis BJM, Brakenhoff RH, Leemans CR. Second field tumors: a new opportunity for cancer prevention? Oncologist. 2005;10:493-500.
30. Brennan CT, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med. 1995;332:429-35.
31. Scholes AG, Woolgar JA, Boyle MA, et al. Synchronous oral carcinomas: independent or common clonal origin? Cancer Res. 1998;58:2003-6.
32. Juven TBY, Zauberman A, George DL, Oren M. Wild-type p53 can mediate sequence specific transactivation of an internal promoter within the MDM-2 gene. Oncogene. 1993;8:3411-6.
33. Haupt YMR, Kazaz D, Oren M. Oncogene MDM-2 conceals thea activation domain of tumour suppressor p53. Nature. 1997;387: 857-60.
34. Shin DM, Lee JS, Lippman SM, et al. p53 expressions: predicting recurrence and second primary tumours in head and neck squa-mous cell carcinoma. J Natl Cancer Inst. 1996;88:519-29.